A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Condition(s):Primary Immunodeficiency Diseases (PID)Last Updated:March 22, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Primary Immunodeficiency Diseases (PID)Last Updated:March 22, 2024Completed
Condition(s):HealthyLast Updated:October 12, 2023Completed
Condition(s):HIV Infections; Pneumococcal InfectionsLast Updated:November 17, 2014Completed
Condition(s):Covid19Last Updated:September 2, 2021Unknown status
Condition(s):Vaccine Adverse Reaction; COVID-19; Vaccine ReactionLast Updated:February 28, 2023Completed
Condition(s):Influenza VaccineLast Updated:July 26, 2022Completed
Condition(s):COVIDLast Updated:August 25, 2022Completed
Condition(s):CIDP; Immunoglobulin Deficiency; Chronic Inflammatory Demyelinating PolyneuropathyLast Updated:August 14, 2023Recruiting
Condition(s):Covid19Last Updated:June 22, 2023Terminated
Condition(s):HIV Infections; Zika Virus InfectionLast Updated:March 21, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.